Chest drain with fibrinolytics is as good as video-assisted thoracoscopic surgery (VATS) in the management of childhood empyema, with fibrinolytics being a cheaper option than VATS, according to a presentation at the APSR 2017 Congress.
Being diagnosed or treated for gastro-oesophageal reflux disease (GORD) has little impact on the survival outcomes of patients with idiopathic pulmonary fibrosis (IPF), according to a study presented as a poster at APSR 2017.
Switching from salmeterol/fluticasone (SFC) to indacaterol/glycopyrronium (IND/GLY) improved lung function in patients with symptomatic, moderate-to-severe, chronic obstructive pulmonary disease (COPD), with a tolerability profile similar to SFC, the multicentre, double-blind, double-dummy, parallel-group phase IV FLASH study has shown.
Individuals who have undergone gastrectomy for stomach cancer may have an added risk of developing tuberculosis (TB), according to a study from South Korea. However, this elevated risk does not appear to extend to nontuberculous mycobacteria (NTM) lung disease.
Having a high initial effusion volume of >1,000 cc was associated with an increased need for surgical intervention after treatment with chest tube thoracostomy (CTT) in patients with loculated pleural effusion, according to a study presented at the APSR 2017 Congress.
About one in five (~20 percent) of lower respiratory tract illnesses (LRTIs) involve respiratory viruses irrespective of the presence of asthma exacerbation, according to a Korea study presented at the 22nd Congress of the Asian Pacific Society of Respirology (APSR) held in Sydney, Australia.
Voriconazole serum concentrations during treatment of chronic pulmonary aspergillosis appear to vary widely in relation to C-reactive protein, according to a study, suggesting that inflammation may reduce drug clearance.
Exertional desaturation is a common feature in patients with interstitial lung disease (ILD), even in those with only mild physiological impairments, reports a study presented at the 22nd Congress of Asian Pacific Society of Respirology (APSR 2017).
In patients with heart failure with reduced ejection fraction (HFrEF) receiving angiotensin-converting-enzyme (ACE) inhibitors, high dosing confers benefits for the risk of death or hospitalization that are similar to that obtained with lower dosing, according to a systematic review and meta-analysis.